Insmed Q3 revenue beats estimates, lifts forecast

Overview

• U.S. biopharma firm's Q3 revenue rose sharply, beating analyst expectations

• Company raised 2026 revenue guidance for BRINSUPRI and ARIKAYCE

• Net loss narrowed from prior year as sales increased

Outlook

• Insmed raises 2026 BRINSUPRI revenue guidance to $1.35 bln–$1.4 bln

• Company lifts 2026 ARIKAYCE revenue forecast to $460 mln–$470 mln

• Insmed continues to anticipate peak revenues for BRINSUPRI above $7 bln and ARIKAYCE above $1 bln

Result Drivers

• BRINSUPRI LAUNCH - Q3 revenue growth was driven by strong U.S. launch of BRINSUPRI, with global sales up 29% from Q2

• ARIKAYCE INTERNATIONAL SALES - ARIKAYCE revenue grew 9% year-over-year, primarily due to strong growth in international markets

• JAPAN APPROVAL - Regulatory approval and launch of BRINSUPRI in Japan contributed to overall performance

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Insmed Incorporated is $196.50, about 102.6% above its October 28 closing price of $96.98

Reuters Recommended Reads

• Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength

• Oct 28 - Viking Therapeutics posts bigger-than-expected Q3 loss as costs rise

• Oct 27 - Novartis slightly misses Q3 net sales estimates, but tops core EPS view

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)